| Date Filed | Type | Description |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 04/24/2023 |
8-K
| Quarterly results |
| 04/24/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 02/24/2023 |
8-K
| Quarterly results |
| 02/24/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/08/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/19/2022 |
4
| CONWAY ROBERT E (Director) has filed a Form 4 on ARCA biopharma, Inc.|
Txns:
| Granted 6,000 options to buy
@ $2.32, valued at
$13.9k
|
|
| 12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/19/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 12/19/2022 |
8-K
| Quarterly results |
| 12/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/09/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 11/03/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/28/2022 |
8-K
| Quarterly results |
| 10/28/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/20/2022 |
8-K
| Quarterly results |
| 08/02/2022 |
8-K
| Quarterly results|
Docs:
|
"Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Westminster, CO, August 2, 2022 – ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “We are in the process of evaluating options for creating stockholder value, including potential development of our assets, partnering and other strategic options.” In May 2022, the Company retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor to explore and evaluate s..." |
|
| 08/02/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/08/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/08/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/08/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/21/2022 |
4
| Ma-Weaver Jacob (10% Owner) has filed a Form 4 on ARCA biopharma, Inc.|
Txns:
| Granted 12,000 options to buy
@ $2.27, valued at
$27.2k
|
|
| 06/21/2022 |
3
| Ma-Weaver Jacob (10% Owner) has filed a Form 3 on ARCA biopharma, Inc. |
| 06/21/2022 |
SC 13D/A
| Funicular Fund, LP reports a 17.9% stake in ARCA biopharma, Inc. |
| 06/21/2022 |
8-K
| Quarterly results |
|